Results with AKLIEF® (trifarotene) Cream, 0.005%

CAN Make clearer skin a possibility for your patients WITH ACNE.1,2

Not an actual patient.

Before & after photos

ACNE RELIEF YOUR PATIENTS CAN SEE.Results from the PIVOTAL studies.

16 year old female photo of face acne vulgaris before AKLIEF® (trifarotene) Cream acne vulgaris treatment. Lesion count 56
16 year old female photo of face acne vulgaris after AKLIEF® (trifarotene) Cream acne vulgaris treatment. Lesion count 6

Study 18251: Double-blind, randomized, vehicle-controlled safety and efficacy 12-week trial of trifarotene cream vs vehicle cream.

IGA=Investigator's Global Assessment.

Male photo of face acne vulgaris before AKLIEF® (trifarotene) Cream acne vulgaris treatment. Lesion count 89
Male photo of face acne vulgaris improvements after AKLIEF® (trifarotene) Cream acne vulgaris treatment. Lesion count 45

STUDY 118295: Open-label, single-arm study of trifarotene cream for 24 weeks.

IGA=Investigator's Global Assessment.

Photo of skin of color chest acne vulgaris before AKLIEF® (trifarotene) Cream acne vulgaris treatment. Lesion count 89
Photo of skin of color chest acne vulgaris after AKLIEF® (trifarotene) Cream acne vulgaris treatment. Lesion count 45

STUDY 118295: Open-label, single-arm study of trifarotene cream for 24 weeks.

PGA=Physician's Global Assessment.

Photo of truncal acne vulgaris before AKLIEF® (trifarotene) Cream acne vulgaris medication
Photo of truncal acne vulgaris improvements after AKLIEF® (trifarotene) Cream acne vulgaris medication

STUDY 118295: Open-label, single-arm study of trifarotene cream for 24 weeks.

PGA=Physician's Global Assessment.

Results from the DUAL study.

Male photo of face acne vulgaris before Dual Study of AKLIEF® (trifarotene) Cream and doxycycline acne vulgaris treatment
Male photo of face acne vulgaris after Dual Study of AKLIEF® (trifarotene) Cream and doxycycline acne vulgaris treatment

STUDY 118295: Phase 4 double-blind, randomized, placebo and vehicle-controlled safety and efficacy 12-week study of trifarotene cream and doxycycline vs vehicle cream and placebo.

IGA=Investigator's Global Assessment.

Male photo of face acne vulgaris before Dual Study of AKLIEF® (trifarotene) Cream and doxycycline acne vulgaris treatment
Male photo of face acne vulgaris after Dual Study of AKLIEF® (trifarotene) Cream and doxycycline acne vulgaris treatment

STUDY 118295: Phase 4 double-blind, randomized, placebo and vehicle-controlled safety and efficacy 12-week study of trifarotene cream and doxycycline vs vehicle cream and placebo.

IGA=Investigator's Global Assessment.

Galderma CareConnect patient savings card can help teen acne patients save money on AKLIEF® (trifarotene) Cream prescriptions

Treating acne doesn't have to break the bank.*

PATIENT SAVINGS CARD
Female serving tennis ball reflects patients with acne vulgaris can achieve clearer skin with AKLIEF® (trifarotene) Cream

HELP YOUR PATIENTS ACHIEVE
CLEARER SKIN.

PATIENT RESOURCES

*The Galderma® CAREConnect™ Program (“Program”) is brought to you by Galderma Laboratories, L.P. (“Galderma”). The Program is only available for commercially unrestricted or commercially restricted/cash paying patients. Patients who are enrolled in state or federally government-run or government-sponsored healthcare plan with a pharmacy benefit are not eligible to use the Galderma CAREConnect Patient Savings Card (“Card”). Any claim under the Program must be submitted by participating pharmacies to one of the Administrators of the Program.

 

References: 1. Tan J, Thiboutot D, Popp G, et al. Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691-1699. 2. Data on File, Galderma Laboratories, L.P.

IMPORTANT SAFETY INFORMATION

Indication: AKLIEF® (trifarotene) Cream, 0.005% is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in patients treated with AKLIEF Cream were application site irritation, application site pruritus (itching), and sunburn. Warnings/Precautions: Patients using AKLIEF Cream may experience erythema, scaling, dryness, and stinging/burning. Use a moisturizer from the initiation of treatment, and, if appropriate, depending upon the severity of these adverse reactions, reduce the frequency of application of AKLIEF Cream, suspend or discontinue use. Avoid application of AKLIEF Cream to cuts, abrasions or eczematous or sunburned skin. Use of “waxing” as a depilatory method should be avoided on skin treated with AKLIEF Cream. Minimize exposure to sunlight and sunlamps. Use sunscreen and protective clothing over treated areas when exposure cannot be avoided.

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Your use of this website is subject to our Updated Privacy Policy. Click here to read more.

Your use of this website is subject to our Updated Privacy Policy. Click here to read more.

up